Feasibility Pilot of Bright Light in the Intensive Care Unit



Status:Recruiting
Healthy:No
Age Range:50 - Any
Updated:1/20/2019
Start Date:December 3, 2018
End Date:March 31, 2024
Contact:Melissa Knauert, MD, PhD
Email:melissa.knauert@yale.edu
Phone:203-785-4163

Use our guide to learn which trials are right for you!

To evaluate the feasibility of providing daytime bright light in the ICU in a pilot
randomized controlled trial.

To evaluate the feasibility of providing daytime bright light in the ICU in a pilot
randomized controlled trial. Feasibility will be assessed via the following metrics: daytime
bright light is acceptable and tolerable to patients and has high fidelity and sustainability
as an intervention.

Inclusion Criteria:

1. Hospital admission ≤30 hours at noon on enrollment day

2. Expected to say in the Medical Intensive Care Unit ≥24 hours after enrollment

3. Age ≥50 years

4. History of hypertension based on chart review and presence of 1 or more home blood
pressure medications

5. Able to understand English

Exclusion Criteria:

1. At significant risk for pre-existing circadian abnormalities:

- Severe chronic brain injury (Injury greater than 30 days ago resulting in the
inability to live independently) OR Acute brain injury of any severity (Injury
less than 30 days ago including acute intracranial bleed, traumatic brain injury,
central nervous system infection, tumor)

- Documented circadian disorder (<1% population) or blind/disease of the optic
nerve

- Current history of substance abuse including alcohol (use in last 30 days)

- Current or recent (last 1 year) shiftwork

2. Home medications include: melatonin, melatonin agonist

3. Transferred from an outside hospital, long-term care, rehabilitation, or acute care
facility

4. History of bipolar disease (Bright light therapy possibly unsafe in this population).

5. Paralyzed (due to injury, disease or medications)

6. Diagnosed with hepatic encephalopathy in the setting of end-stage liver disease

7. Homeless
We found this trial at
1
site
New Haven, Connecticut 06520
Principal Investigator: Melissa P Knauert, MD, PhD
?
mi
from
New Haven, CT
Click here to add this to my saved trials